Smith & Nephew (SNN)
NYSE: SNN
· Real-Time Price · USD
36.61
-0.17 (-0.46%)
At close: Aug 14, 2025, 3:59 PM
36.38
-0.63%
Pre-market: Aug 15, 2025, 09:24 AM EDT
Smith & Nephew Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|
| Advanced Wound Management Revenue | 1.68B | 1.61B | 1.51B | 1.5B | 1.31B | 1.38B | 1.27B |
| Advanced Wound Management Revenue Growth | +4.67% | +6.22% | +1.07% | +14.20% | -5.07% | +8.24% | n/a |
| Orthopaedics, Sports Medicine and ENT and Advanced Wound Management Revenue | 5.81B | 5.55B | 5.21B | 5.21B | n/a | n/a | n/a |
| Orthopaedics, Sports Medicine and ENT and Advanced Wound Management Revenue Growth | +4.70% | +6.40% | +0.06% | n/a | n/a | n/a | n/a |
| Orthopaedics, Sports Medicine and Ear Nose and Throat Revenue | 4.13B | 3.94B | 3.7B | 3.72B | n/a | n/a | n/a |
| Orthopaedics, Sports Medicine and Ear Nose and Throat Revenue Growth | +4.72% | +6.48% | -0.35% | n/a | n/a | n/a | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|
| China Revenue | 319M | 352M |
| China Revenue Growth | -9.38% | n/a |
| United States Of America Revenue | 2.76B | 2.66B |
| United States Of America Revenue Growth | +3.99% | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Dec 31, 2024 | Jun 29, 2024 | Dec 31, 2023 | Jun 30, 2023 | Dec 31, 2022 | Jun 30, 2022 | Dec 31, 2021 | Jun 30, 2021 | Dec 31, 2020 | Jun 30, 2020 | Dec 31, 2019 | Jun 30, 2019 | Dec 31, 2018 | Jun 30, 2018 | Dec 31, 2017 | Jun 30, 2017 | Dec 31, 2016 | Jun 30, 2016 | Dec 31, 2015 | Jun 30, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 1.53B | 1.59B | 1.51B | 1.43B | 1.46B | 1.28B | 1.41B | 1.25B | 1.38B | 1.19B | 1.25B | 1.25B | 1.28B | 1.08B | 1.3B | 1.2B | 1.21B | 1.07B | 1.19B | 1.21B | 1.13B |
| Selling, General, and Administrative Revenue Growth | -3.79% | +5.43% | +5.30% | -1.65% | +13.47% | -9.00% | +12.52% | -9.33% | +15.93% | -4.25% | -0.72% | -1.88% | +17.88% | -16.47% | +8.52% | -1.24% | +13.27% | -9.70% | -1.90% | +7.38% | n/a |
| Research and Development Revenue | 144.29M | 152M | 137M | 219M | 166M | 222M | 174M | 226M | 171M | 195M | 148M | 181M | 139M | 154M | 116M | 122M | 107M | 132M | 113M | 123M | 110M |
| Research and Development Revenue Growth | -5.07% | +10.95% | -37.44% | +31.93% | -25.23% | +27.59% | -23.01% | +32.16% | -12.31% | +31.76% | -18.23% | +30.22% | -9.74% | +32.76% | -4.92% | +14.02% | -18.94% | +16.81% | -8.13% | +11.82% | n/a |